

Neuralstem, Inc.  
Form 8-K  
March 16, 2015

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): March 16, 2015**

---

**Neuralstem, Inc.**

**(Exact name of registrant as specified in Charter)**

**Delaware**    **000-1357459**    **52-2007292**  
**(State or other jurisdiction of**  
**incorporation or organization)**                              **(Commission File No.)**    **(IRS Employee Identification No.)**

**20271 Goldenrod Lane, 2<sup>nd</sup> Floor**  
**Germantown, Maryland 20876**

**(Address of Principal Executive Offices)**

**(301) 366-4960**

**(Issuer Telephone number)**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02. Results of Operations and Financial Condition.**

On March 16, 2015, Neuralstem, Inc. (the “Company”) reported fiscal 2014 fourth quarter and year-end business results for the year ended December 31, 2014 and provided an update on clinical programs and business highlights. The press release is attached as Exhibit 99.01 and is incorporated herein by reference.

The information furnished under Items 2.02, including the accompanying Exhibit 99.01 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall such information be deemed to be incorporated by reference in any subsequent filing by the Company under the Securities Act of 1933 or the Exchange Act, regardless of the general incorporation language of such filing, except as specifically stated in such filing.

**Item 9.01. Financial Statement and Exhibits.**

**Exhibit Number Description**

99.01 Press Release Dated March 16, 2015

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

NEURALSTEM, INC

By: /s/ I. Richard Garr  
I. Richard Garr

Chief Executive Officer

Dated: March 16, 2015



**Exhibit Index**

**Exhibit Number Description**

99.01	Press Release Dated March 16, 2015
-------	------------------------------------